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Atherosclerotic cardiovascular disease risks in chronic hemodi- Cardiovascular events are the leading cause of death
alysis patients. in chronic hemodialysis patients [1]. Identification of
Background. Cardiovascular diseases are the most common their risk factors is important in order to devise preven-
causes of death among chronic hemodialysis patients, yet the
tive and interventional strategies. Intuitively, it appearsrisk factors for these events have not been well established.
reasonable to assume that the traditional cardiovascularMethods. In this cross-sectional study, we examined the rela-
tionship between several traditional cardiovascular disease risk risk factors for the general population are also applicable
factors and the presence or history of cardiovascular events in to the hemodialysis patients, and that hemodialysis pa-
936 hemodialysis patients enrolled in the baseline phase of the tients suffer more cardiovascular diseases because these
Hemodialysis Study sponsored by the U.S. National Institutes
risk factors are present to a greater extent. For example,of Health. The adjusted odds ratios for each of the selected risk
hypertension is especially prevalent in this populationfactors were estimated using a multivariable logistic regression
[2]. Against this hypothesis are the observations that themodel, controlling for the remaining risk factors, clinical center,
and years on dialysis. other traditional risk factors, such as hypercholesterol-
Results. Forty percent of the patients had coronary heart emia, may not be present to a greater extent in the
disease. Nineteen percent had cerebrovascular disease, and hemodialysis population compared with the general pop-23% had peripheral vascular disease. As expected, diabetes and
ulation [3, 4].smoking were strongly associated with cardiovascular diseases.
Limited available data further suggest that some ofIncreasing age was also an important contributor, especially
in the group less than 55 years and in nondiabetic patients. the traditional cardiovascular risk factors are not applica-
Black race was associated with a lower risk of cardiovascular ble to the hemodialysis patients. For example, in a cross-
diseases than non-blacks. Interestingly, neither serum total sectional study, Lowrie and Lew reported that the overall
cholesterol nor predialysis systolic blood pressure was associ- mortality in chronic hemodialysis patients increased ex-ated with coronary heart disease, cerebrovascular disease, or
ponentially when serum total cholesterol decreased fromperipheral vascular disease. Further estimation of the coronary
the range of 200 to 250 mg/dL to less than 100 mg/dLrisks in our cohort using the Framingham coronary point score
suggests that traditional risk factors are inadequate predictors [5]. More recently, Zager et al reported a “U”-shaped
of coronary heart disease in hemodialysis patients. curve in the relationship between predialysis systolic
Conclusions. Some of the traditional coronary risk factors in blood pressure and mortality, with the lowest mortality
the general population appear to be also applicable to the hemo-
observed in the group with blood pressure between 160dialysis population, while other factors did not correlate with
and 179 mm Hg [6]. These observations raise questionsatherosclerotic cardiovascular diseases in this cross-sectional
as to whether the traditional cardiovascular risk factorsstudy. Nontraditional risk factors, including the uremic milieu
and perhaps the hemodialysis procedure itself, are likely to be are applicable to the chronic hemodialysis population.
contributory. Further studies are necessary to define the cardio- Many outcome studies in the chronic hemodialysis
vascular risk factors in order to devise preventive and interven- population, including those addressing risk factors fortional strategies for the chronic hemodialysis population.
cardiovascular diseases, have used overall mortality and
hospitalization as their outcome measures. Very few, in
fact, examined the association of potential risk factorsKey words: coronary risk factors, uremia, blood pressure, dialysis, se-
rum total cholesterol, vascular disease. with the cardiovascular events themselves.
The goal of the present study was to evaluate theReceived for publication October 8, 1999
prevalence and severity of atherosclerotic cardiovascularand in revised form January 18, 2000
Accepted for publication January 25, 2000 diseases in a representative chronic hemodialysis popula-
tion. In addition, we examined the presence of traditionalÓ 2000 by the International Society of Nephrology
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Table 1. Definitions of the index of co-existing diseases (ICED) forcardiovascular risk factors and the relationship of these
atherosclerotic cardiovascular diseases
putative risk factors to clinical atherosclerotic cardiovas-
Score Definitioncular diseases in this population, using a cross-sectional
Coronary heart diseasedesign. Since risk factors might differ among various end
0 Absence of disease in past or presentorgans, we examined coronary heart disease, cerebrovas-
1 Diagnosis of coronary heart disease in the past
cular disease, and peripheral vascular disease individu- Ischemia on electrocardiogram or other diagnostic tests
Stable or exertional angina or angina during hemodialysisally in this study.
2 History of myocardial infarction
Evidence of myocardial infarction on electrocardiogram
History of coronary revascularization proceduresMETHODS
3 Angina at rest
Acute myocardial infarction within the past 3 monthsStudy design
Cerebrovascular disease
The data analysis on cardiovascular risks was based 0 Absence of disease in past or present
1 Diagnosis of cerebrovascular disease in the paston a cross-sectional study of the first 1000 patients re-
Asymptomatic carotid stenosis or history of transientcruited into the baseline phase of the Hemodialysis
ischemic attacks (TIAs)
(HEMO) Study. The HEMO Study is sponsored by the History of carotid endarterectomy
2 Multiple TIAs in the pastU.S. National Institute of Diabetes, Digestive, and Kid-
Current usage of anticoagulants for cerebrovascular diseaseney Diseases; the full-scale trial began in 1995. Details
History of stroke with no or mild residual neurological deficits
regarding the design of the HEMO Study have been 3 History of stroke with major residual neurological deficits
Peripheral vascular diseasepublished elsewhere [7]. In brief, the study is a multicen-
0 Absence of disease in past or presentter, prospective, randomized, clinical trial designed to
1 Diagnosis of peripheral vascular disease or aortic aneurysm
evaluate the effect of dialyzer urea and b2-microglobulin in the past
2 History of amputation of digits or extremities secondary toclearances on the morbidity and mortality of patients.
vascular diseasePatients were eligible for inclusion into the HEMO
History of peripheral arterial bypass or aortic aneurysm
Study if they were between the ages of 18 and 80 years, repair
Intermittent claudicationhad been receiving chronic hemodialysis three times per
Recurrent cellulitis, skin infections, or toe gangrenes second-week, and had residual renal clearance of urea that was
ary to vascular disease
less than 1.5 mL/min/35 L of urea distribution volume. Vascular disease currently requiring anticoagulants
3 History of knee amputationAmong the exclusion criteria were unstable angina, New
Pain at rest secondary to peripheral vascular diseaseYork Heart Association Class IV congestive heart failure
Inoperable vascular disease
despite medical management, and predialysis serum
albumin , 3.0 g/dL.
Data procurement
of Co-Existing Diseases (ICED), a coding system that
Demographic, medical, and socioeconomic informa-
classifies the presence and severity of 19 different dis-tion were obtained once patients were enrolled into the
eases and 11 physical impairments [8]. The comorbiditybaseline phase of the study. Information that was ob-
index of individual patients is scored with a value rangingtained included age, race, gender, height, predialysis and
from 0 to 3, with 0 indicating the absence of diseaseprescribed dry weight, predialysis and postdialysis sitting
and increasing values indicating increasing severity of theblood pressures (single measurements), primary renal
disease. The focus of the present report is on atheroscle-diagnosis, duration of end-stage renal disease (ESRD),
rotic events, namely, coronary heart disease, cerebrovas-diabetic status (based on past or current use of hypogly-
cular disease, and peripheral vascular disease. The scoringcemic agents), previous extremity amputation, and his-
system for each of these diseases is described in Table 1.tory of cigarette smoking.
Blood samples for total cholesterol were obtained pre-During the fifth week of the study, while the patients
dialysis, as part of the routine clinical protocol, withinwere still in the baseline phase, their comorbid medical
one month of enrollment without specific instructionsconditions were assessed and recorded on a standardized
to the patients. Serum cholesterol concentrations wereform. The form was completed at each clinical center by
measured by the clinical laboratories associated with in-specially trained study coordinators. The information
dividual dialysis centers. Fractionation of serum choles-available for the completion of the form included chart
terol and triglyceride determination were not performed.progress notes, list of current medications, and the most
recent laboratory data, chest x-ray report, electrocardio-
Statistical analysesgram, and hospital discharge summary and was supple-
Of the initial 1000 patients enrolled in the baselinemented by interviews of the patients, family members,
phase of the HEMO Study, 64 of them did not haveprimary nephrologists, and dialysis staff as necessary.
The comorbidities were catalogued using the Index complete information for analyses of cardiovascular risks
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Table 2. Prevalence and severity of atherosclerotic cardiovasculardescribed herein. Therefore, only the remaining 936 pa-
diseases in the HEMO Study cohort
tients are included hereafter in our report.
Scorea 0 1 2 3Unadjusted and adjusted odds ratios describing the
Coronary heart disease 60% 14% 24% 2%association of selected cardiovascular risk factors with
Cerebrovascular disease 81% 4% 14% 1%each of three disease categories (coronary heart disease,
Peripheral vascular disease 77% 6% 10% 7%
cerebrovascular disease, and peripheral vascular disease)
a The scoring system is defined in Table 1were obtained by univariable and multivariable logistic
regression, respectively. Odds ratio is expressed as the
ratio of the odds of having any level of disease between
the indicated levels of the risk factor. The cardiovascular was higher than that in the U.S. chronic hemodialysis
population [1] and might be related to a preponderancerisk factors included in the multivariable logistic regres-
sions were those commonly used in the Framingham of urban dialysis units in the HEMO Study. Caucasians
accounted for 33% of the cohort. The mean (6 SD) ageStudy for the general population, namely, age, gender,
race, presence or absence of diabetes mellitus, history of the patients was 58 6 14 years. The mean duration
on dialysis was 4.3 6 4.5 years.or current smoking status, and serum total cholesterol,
with the addition of predialysis systolic and diastolic The 42% of patients with diabetes mellitus in this
study was similar to that in the U.S. hemodialysis popula-blood pressures. Clinical center and total number of
years on dialysis were also included as predictor variables tion. Fifty-two percent of the patients either smoked
cigarettes at the time of entry to the study or had ain the multivariable logistic regressions, so that the ad-
justed odds ratios for each of the selected cardiovascular previous history of smoking. The number of cigarettes
smoked was not quantitated. The mean (6 SD) serumrisk factors are controlled for the remaining cardiovascu-
lar risk factors, clinical center, and years of dialysis. total cholesterol concentration was 174 6 40 mg/dL,
which was similar to that previously reported for chronicFor graphical presentation, nonparametric logistic re-
gression analysis with cubic smoothing splines [9] was hemodialysis patients [3, 4]. The mean predialysis sys-
tolic and diastolic blood pressures were 152 6 25 andused to relate the probability of the three disease out-
comes to the quantitative risk factors age, blood pres- 82 6 15 mm Hg, respectively. The distributions of total
cholesterol concentration, systolic blood pressure, andsure, and total cholesterol, while controlling for clinical
centers, years on dialysis, and the remaining cardiovascu- diastolic blood pressure are shown in Figure 1. Total
cholesterol concentrations and predialysis blood pres-lar risk factors examined. These analyses indicated a
significant nonlinear relationship between age and the sures of the study cohort were further classified according
to the definitions provided by the National Cholesterollogarithm of the odds of coronary heart disease (P 5
0.02). There was also a trend for a nonlinear relationship Education Program Adult Treatment Panel II [10] and
the Sixth Report of the Joint National Committee onbetween age and the logarithm of the odds of peripheral
vascular disease (P 5 0.10). Therefore, in the logistic Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (Table 3) [11].regression analyses, the relationships of the odds ratios
of the respective disease categories with age in the entire
Association between traditional Framingham riskcohort were modeled with separate terms for age ,55
factors and probability of cardiovascular diseasesyears and age .55 years.
The association between traditional cardiovascular
risk factors and the three forms of cardiovascular dis-
RESULTS
eases (coronary, cerebrovascular, and peripheral) in our
Prevalence and severity of atherosclerotic patients was first examined using separate univariable
cardiovascular diseases logistic regression models. The results are presented in
Table 4. In this analysis, increasing age and diabetesAs can be seen in Table 2, 40% of the patients had
coronary heart disease, 19% had cerebrovascular dis- were strongly associated with all three types of disease.
Smoking was associated with cerebrovascular and pe-ease, and 23% had peripheral vascular disease. Among
those with coronary heart disease, cerebrovascular dis- ripheral vascular diseases, but not with coronary heart
disease. Conversely, serum total cholesterol was associ-ease, and peripheral vascular disease, the most prevalent
category was that with a severity score of two. ated with coronary heart disease, but not with cerebro-
vascular and peripheral vascular diseases. Of note is that
Framingham risk factors in the present study cohort predialysis systolic blood pressure was not associated with
any of the three types of atherosclerotic cardiovascularThe levels of traditional Framingham cardiovascular
risk factors were examined in this hemodialysis study diseases. In contrast, predialysis diastolic blood pressure
and the duration on dialysis were inversely associatedcohort. There was a slight preponderance (53%) of fe-
males. Sixty-four percent of the patients were black, which with coronary heart disease.
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cular diseases is depicted graphically in Figure 2. The
relationship between age and peripheral vascular disease
was weaker than that between age and coronary heart
disease in general.
There were interactions between age and diabetic sta-
tus that affected their associations with atherosclerotic
cardiovascular diseases. Overall, age had a stronger asso-
ciation with cardiovascular diseases in the absence of
diabetes than in the presence of diabetes. In the presence
of diabetes, the odds ratio of developing coronary heart
disease was 1.48 (P , 0.0001) for every 10 year increase
in age, while in absence of diabetes, the odds ratio was
2.15 (P , 0.0001). In the presence of diabetes, there was
no significant linear or nonlinear association between
age and cerebrovascular or peripheral vascular disease.
In the absence of diabetes, however, the odds ratios of
developing cerebrovascular disease and peripheral vas-
cular diseases were 1.96 (P , 0.0001) and 1.74 (P ,
0.0001), respectively, for each 10 year increase in age.
Smoking directly correlated (odds ratio 5 1.68, P 5
0.008) with cerebrovascular disease. Smoking was also
associated with peripheral vascular disease (odds ratio 5
1.74, P 5 0.003), but not with coronary heart disease.
Black race was associated with a 36% reduction (P 5
0.017) in the odds of having coronary heart disease and
46% reduction (P 5 0.003) in peripheral vascular dis-
ease, but it had no influence on cerebrovascular disease.
In the multivariable regression model, there was no
statistically significant correlation between serum total
cholesterol concentration and any of the cardiovascular
diseases by either linear regression (Table 5) or nonlin-
ear regression (data not shown) analysis. The relation-
ship between cholesterol concentration and the probabil-
ity of having the various forms of cardiovascular diseases
is depicted graphically in Figure 3. As was the case with
total cholesterol, there was no significant linear (Table
Fig. 1. Distribution of serum total cholesterol levels (A) and predialysis 5) nor nonlinear (data not shown) association between
systolic (B) and predialysis diastolic (C) blood pressure values in the
predialysis systolic blood pressures and any of the cardio-HEMO Study cohort.
vascular diseases. The relationship between predialysis
systolic blood pressure and the probability of having
the various forms of cardiovascular diseases is depicted
graphically in Figure 4.Results of the multivariable regression model are pre-
sented in Table 5. As expected, the presence of diabetes
Association between primary renal diagnosis andmellitus was associated with a 65% increase (P 5 0.002)
cardiovascular diseasesin the odds of having coronary heart disease and a 3.59-
When the patients were categorized based on theirfold increase (P 5 0.0) in peripheral vascular disease.
primary renal diagnosis, those with diabetic nephropathyInterestingly, there was no statistically significant associ-
had the highest prevalence of atherosclerotic cardiovas-ation between diabetes and cerebrovascular disease.
cular diseases (Table 6). Compared with glomerular dis-As expected, increasing age was strongly associated
eases, hypertensive nephrosclerosis was associated with
with atherosclerotic diseases, particularly in the younger a similar or higher prevalence of cardiovascular diseases.
age group. In patients below 55 years old, the odds of
having coronary heart disease increased by a factor of
DISCUSSION2.68 for every 10 year increase in age, while the odds
Prevalence of cardiovascular diseasesincreased by a factor of only 1.47-fold for every 10 years
in patients older than 55 years old. The relationship Approximately 40% of the present study cohort had
evidence of coronary heart disease, while 19 and 23%between age and the probability of the various cardiovas-
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Table 3. Serum total cholesterol concentrations and predialysis blood pressures in the HEMO Study cohort classified according to the
definitions of NCEPa and JNC VIb
Percentage of
Number of patients population
Serum total cholesterol
,200 mg/dL 725 77.5
200–239 mg/dL 152 16.2
$240 mg/dL 59 6.3
Blood pressure Systolicc Diastolicc
Optimal BP ,120 and ,80 69 7.4
Normal BP ,130 and ,85 77 8.2
High-normal BP 130–139 or 85–89 124 13.3
Stage 1 hypertension 140–159 or 90–99 291 31.2
Stage 2 hypertension 160–179 or 100–109 232 24.8
Stage 3 hypertension $180 or $110 141 15.1
a NCEP, National Cholesterol Education Program Adult Treatment Panel II [10]
b JNC VI, Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure [11]
c When systolic and diastolic blood pressures fall into different categories, the higher category was selected to classify the individual blood pressure status; each
patient was classified in only one category
Table 4. Univariable logistic regression analysis of the odds ratio of atherosclerotic cardiovascular diseases for potential risk factors
in the HEMO Study cohort
Coronary Cerebrovascular Peripheral vascular
heart disease disease disease
O.R.a P O.R. P O.R. P
Gender male 0.89 0.392 1.17 0.354 1.19 0.274
Race Black 0.77 0.057 1.06 0.749 0.67 0.011
Age per 10 year increase 1.92 0.000 1.56 0.000 1.35 0.000
Presence of diabetes mellitus 2.15 0.000 1.61 0.004 3.17 0.000
Smokingb 1.11 0.438 1.79 0.001 1.77 0.000
Cholesterol per 20 mg/dL increase 1.10 0.004 1.02 0.609 1.04 0.273
Systolic BP per 20 mm Hg increasec 1.04 0.424 1.11 0.127 1.03 0.662
Diastolic BP per 20 mm Hg increasec 0.76 0.004 0.96 0.698 0.83 0.079
Dialysis duration per 5 year increase 0.79 0.003 0.90 0.262 0.79 0.017
a Odds ratio
b History of or current smoking
c Predialysis blood pressure
Table 5. Multivariable logistic regression analysis of the odds ratio of atherosclerotic cardiovascular diseases for potential risk factors
in the HEMO Study cohort
Coronary Cerebrovascular Peripheral vascular
heart disease disease disease
O.R.a P O.R. P O.R. P
Gender male 1.10 0.567 1.18 0.401 1.12 0.539
Race black 0.64 0.017 0.97 0.901 0.54 0.003
Age ,55 years per 10 year increase 2.68 0.000 1.72 0.007 1.44 0.030
Age .55 years per 10 year increase 1.47 0.001 1.51 0.003 1.09 0.550
Presence of diabetes mellitus 1.65 0.002 1.41 0.074 3.59 0.000
Smokingb 1.08 0.647 1.68 0.008 1.74 0.003
Cholesterol per 20 mg/dL increase 1.04 0.343 0.99 0.775 0.99 0.740
Systolic BP per 20 mm Hg increasec 0.98 0.778 1.09 0.228 0.98 0.750
Dialysis duration per 5 year increase 1.02 0.820 1.10 0.385 1.06 0.589
a Odds ratio
b History of or current smoking
c Predialysis blood pressure
had evidence of cerebrovascular disease and peripheral Data System collected in 1996, which showed 42% coro-
nary heart disease, 16% cerebrovascular disease, andvascular disease, respectively. These prevalence data are
very similar to those described in the Dialysis Morbidity 23% peripheral vascular disease [1]. This prevalence of
coronary heart disease in the hemodialysis patients isand Mortality Wave 2 Study of the United States Renal
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able model. Smoking, on the other hand, was associated
with the cerebrovascular and peripheral vascular disease,
but not with coronary heart disease. As in the general
population, increasing age was associated with the devel-
opment of all three forms of cardiovascular disease in
the entire cohort. This age dependency, however, was
lost for cerebrovascular and peripheral vascular diseases
in the presence of diabetes, suggesting that diabetes ex-
erts a more powerful influence than age on these disor-
ders. The finding that diabetes, smoking, and age are the
most reproducible traditional risk factors associated with
cardiovascular diseases is consistent with prior studies
in the ESRD population [1, 13, 14].
Racial differences
Multivariable analysis revealed that the black race was
associated with a 36% reduction in coronary heart dis-
ease and a 46% reduction in peripheral vascular disease,
but it was not associated with a reduction in cerebrovas-
cular disease (Table 5). These data on coronary heart
disease are consistent with results of prior studies and
the lower mortality secondary to all causes as well as
cardiovascular disease-specific mortality in the black
ESRD population [14, 15]. The reasons for this racial
difference, however, remain unknown. One might hy-
pothesize that black patients have a higher percentage
of ESRD secondary to hypertension, and hypertensive
nephrosclerosis is less likely to be associated with cardio-
vascular disease than are other causes of renal disease,
such as diabetes. While nephrosclerosis as a cause of
ESRD was indeed more common in the blacks (42 vs.
17%), diabetic nephropathy was also more common in
blacks than in Caucasians (37 vs. 33%). While the preva-
lence of coronary heart disease in nephrosclerosis wasFig. 2. Relationship between age and probability of having coronary
lower than that in diabetic nephropathy, it was greaterheart disease (A), cerebrovascular disease (B), and peripheral vascular
disease (C). The probabilities are adjusted for all other covariates de- than that in glomerular diseases (Table 6). Thus, differ-
scribed in the Methods section, including duration of dialysis and differ- ences in the primary renal diagnosis do not appear toent dialysis centers. The broken lines represent 95% confidence inter-
be a satisfactory explanation for the lower coronary risksvals. There is a significant positive association between each of these
disease categories and age. The association of age with the risk of in blacks. Alternatively, one might speculate that there
coronary heart disease (expressed as the natural logarithm of the odds) are factors other than the traditional Framingham riskwas significantly nonlinear (P 5 0.021), with a stronger relationship
factors that contribute to atherosclerotic vascular dis-observed at lower ages.
eases in the chronic hemodialysis patients and that these
factors are less common or less severe in the black dial-
ysis patients. For example, homocysteine metabolism has
been noted to be more efficient in blacks [16]. Against
substantially higher than that in the general population, this hypothesis, however, are the higher lipoprotein(a)
which has been reported to be 2 to 26% depending on levels reported in blacks [17]. It should be noted, how-
age and gender [12]. ever, that these two studies were performed in nonure-
mic subjects.
Traditional risk factors applicable to
hemodialysis population Relationship between cholesterol or blood pressure
with clinical outcomeAs expected, diabetes was found to be strongly associ-
ated with both coronary heart disease and peripheral The most intriguing results of the multivariable analy-
vascular disease, but interestingly, it was not significantly sis were the lack of association between serum total
cholesterol level (Table 5 and Fig. 3) or predialysis sys-associated with cerebrovascular disease in the multivari-
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Fig. 3. Relationship between serum total cholesterol concentration and Fig. 4. Relationship between predialysis systolic blood pressure andprobability of having coronary heart disease (A), cerebrovascular dis- probability of having coronary heart disease (A), cerebrovascular dis-ease (B), and peripheral vascular disease (C). The probabilities are ease (B), and peripheral vascular disease (C). The probabilities areadjusted for all other covariates described in the Methods section, adjusted for all other covariates described in the Methods section,including duration of dialysis and different dialysis centers. The broken including duration of dialysis and different dialysis centers. The brokenlines represent 95% confidence intervals. There is no statistically sig- lines represent 95% confidence intervals. There is no statistically sig-nificant linear or nonlinear relationship between serum cholesterol con- nificant linear or nonlinear relationship between predialysis systoliccentration and the natural logarithm of the odds of developing any of blood pressure and the natural logarithm of the odds of developing anythe three types of atherosclerotic diseases. of the three types of atherosclerotic diseases.
tolic blood pressure (Table 5 and Fig. 4) and the presence The risk continued to increase as the cholesterol levels
of atherosclerotic cardiovascular diseases, despite the decreased. This is distinctly different from the relation-
well-established effects of serum total cholesterol and ship in the general population, in which cardiovascular
systolic blood pressure in the general population [18, 19]. mortality decreases continuously as total cholesterol level
Coincidentally, the results of the present study on choles- decreases from 200 to 240 mg/dL to a level of approxi-
terol and blood pressure are not inconsistent with those mately 140 mg/dL [18]. The argument can be made that
in other cohort studies. Lowrie and Lew used logistic a low cholesterol level is an indicator of malnutrition and
regression to evaluate the relative risk of hypercholester- confounds the risk factor analysis. However, it remains
olemia in 12,000 hemodialysis patients [5]. They noted difficult to reconcile the observation that total choles-
a significantly increased overall mortality risk for total terol values between 150 and 200 mg/dL (relatively nor-
serum cholesterol levels at 150 to 200 mg/dL, compared mal values in the general population) should be associ-
ated with malnutrition in the hemodialysis population.with the risk for cholesterol levels at 200 to 250 mg/dL.
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Table 6. Prevalence of atherosclerotic cardiovascular diseases according to primary renal diagnosis
Coronary Cerebrovascular Peripheral vascular
N heart disease disease disease
Diabetic nephropathy 326 51% 24% 36%
Hypertensive nephrosclerosis 298 39% 19% 16%
Glomerular diseases 141 27% 18% 13%
Others 143 32% 13% 20%
Overall 908a 40% 19% 23%
a Of the 936 patients in the study, 908 had a primary renal diagnosis, while 28 were classified as unknown and were excluded from this table
Table 7. Hypothetical risk of development of de novo coronary heart disease in the HEMO Study cohort based on their coronary scores
as defined in the Framingham Studya
Male Female
HEMO Study Framingham HEMO Study Framingham
Age group N b Riskc Riskd N b Riskc Riskd
30–39 years 30 0.9 1.0 28 0.3 NA
40–49 years 56 3.6 4.4 43 1.6 0.9
50–59 years 45 8.3 9.5 40 3.2 3.6
60–69 years 29 13.0 11.6 70 9.0 7.5
70–74 years 13 14.3 NAe 17 11.7 NAe
a By definition, only patients without any evidence of coronary heart disease, cerebrovascular disease, and peripheral vascular disease are included in this analysis.
The variables employed to calculate the coronary score in the Framingham Heart Study were age, gender, diabetic status, systolic blood pressure, serum total
cholesterol, left ventricular hypertrophy by electrocardiography, and smoking status [24]. The hypothetical risks of developing de novo coronary heart disease over
6 years in the HEMO Study cohort were calculated based on these patients’ actual coronary scores. In other words, these were the calculated risks for the HEMO
Study patients if they were nonuremic subjects, but not their actual risks. The results show that, based on their coronary scores, HEMO Study patients did not have
significantly higher risk of developing coronary heart disease than the general population
b Number of patients in the HEMO Study cohort who did not have any evidence of coronary heart disease, cerebrovascular disease, and peripheral vascular
disease, categorized according to age
c Calculated probabilities of developing de novo coronary heart disease over 6 years in the HEMO Study patients, based on their coronary point scores. These
were not their actual probabilities
d Probabilities of developing coronary heart disease over 6 years in the Framingham Study estimated from published tables [25]
e Data not available
An unconventional relationship between predialysis 120 and 140 mm Hg (a relatively normal value in the
general population) reflect cardiomyopathy in the hemo-systolic blood pressure and outcome has also been re-
ported by Port et al [20] and Zager et al [6]. Analyzing dialysis population. A caveat that should be kept in mind
data from 4839 chronic hemodialysis patients in the Case is that the blood pressures reported in the present study
Mix Adequacy Study of the U.S. Renal Data System and many other studies were predialysis values. Postdial-
using Cox regression models, Port et al found that higher ysis and interdialytic blood pressures were likely to be
predialysis systolic blood pressure (from 150 to .180 different from predialysis values. Data regarding the im-
mm Hg) was not associated with higher mortality risk. pact of blood pressure at these various time points on
When predialysis systolic blood pressure decreased be- clinical outcome are limited [6, 20].
low the reference group (120 to 149 mm Hg), however, It should also be noted that the outcome measure
relative mortality risk increased and reached statistically used in the previously mentioned studies varied. Total
significant values at pressures below 110 mm Hg. Using mortality was the outcome measure in the study of Low-
Cox regression analysis with fixed and time-varying cova- rie and Lew for cholesterol [5] and the study of Port et
riables, Zager et al found a “U”-shaped relationship al for blood pressure [20]. Cardiovascular mortality was
between systolic blood pressure and cardiovascular mor- the outcome measure in the study of Zager et al for blood
tality. Of interest was that systolic blood pressure in the pressure [6], while three individual types of nonfatal
range of 160 to 179 mm Hg was associated with the low- atherosclerotic cardiovascular events were the outcome
est mortality. This is distinctly different from the mono- measures in the present study.
phasic curve commonly seen in the general population
Cerebrovascular diseases[21] and nondialysis patients with underlying ischemic
heart disease [22]. One may hypothesize that low blood Studies using cerebrovascular events as clinical out-
comes are very limited. Iseki and Fukiyama reported apressure is an indicator of cardiomyopathy, which may
confound the risk factor analysis. It remains necessary positive association of predialysis systolic blood pressure,
but not age and smoking, with stroke in a Japaneseto reconcile that systolic blood pressure values between
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chronic hemodialysis population [23]. In contrast, we may bias the results. First, there might be a survival
bias, in that the patients with the highest serum totalfound an association between age or smoking, but not
cholesterol levels and highest blood pressure might havepredialysis systolic blood pressure, and cerebrovascular
already died and therefore could not be enrolled in thedisease (Table 5).
study. Second, a cause versus effect bias might exist.
Coronary scores in the HEMO Study cohort and the In this scenario, hypertension and hypercholesterolemia
Framingham cohort might have been risk factors for the development of
atherosclerotic cardiovascular diseases, but as a resultThe unconventional associations between serum total
of these diseases, malnutrition and cardiomyopathy de-cholesterol level or blood pressure and cardiovascular
veloped, which, in turn, lowered the levels of serumevents described previously in this article suggest that
cholesterol and blood pressure, respectively. Third, theretraditional coronary risk factors may not be sufficient
could have been a treatment effect. According to thisto explain the extent of cardiovascular diseases in the
hypothesis, modifiable risk factors such as hypercholes-hemodialysis population. This hypothesis is supported
terolemia and hypertension could have been treatedby further analyses in which the coronary point scores
more aggressively once the diagnosis of cardiovascularin our HEMO Study cohort were compared with those
diseases had been made. Consequently, at the time ofin the Framingham Study cohort (Table 7). The coronary
the analysis, these risk factors no longer correlated withpoint score was devised to assess the potential risk of
the diseases.nonuremic subjects in developing de novo coronary
It should further be cautioned that even though weheart disease [24]. The variables used to generate the
label these cardiovascular diseases in the hemodialysisscore were age, gender, diabetic status, smoking status,
patients as atherosclerotic, the exact histology of theserum total cholesterol level, systolic blood pressure,
lesions in their blood vessels may be different from thoseand left ventricular hypertrophy by electrocardiography.
in nonuremic subjects.Using this scoring system, we computed the projected
risk of developing coronary heart disease in a subset of Conclusions
our HEMO Study cohort who did not have a history of
In conclusion, we found a high prevalence of athero-any atherosclerotic cardiovascular disease at baseline
sclerotic cardiovascular diseases in the chronic hemodial-and compared the results to the published data on the
ysis patients. Several of the traditional coronary risk fac-Framingham population.
tors in the general population appear to be applicableAs seen in Table 7, the risks of developing de novo
to the hemodialysis population. The levels of serum total
coronary heart disease in six years for each age group cholesterol and systolic blood pressure, however, did not
in our HEMO Study subset, as predicted by traditional bear the same relationship to atherosclerotic cardiovas-
coronary point scores, were similar to those in the Fram- cular diseases in the hemodialysis population as they do
ingham study participants predicted by the same scoring in the general population or as in the two recent reports
system [25]. Although longitudinal data on our HEMO in chronic hemodialysis patients [5, 6]. The risk factors
Study patients are currently not available, it has been for coronary heart disease, cerebrovascular disease, and
well established that the incidence and prevalence of peripheral vascular disease may also differ from each
coronary heart disease in similar populations are at least other. Long-term prospective and interventional studies
severalfold greater [12, 26, 27], and the cardiovascular are urgently needed to clarify the impact of serum choles-
mortality is 10- to 20-fold greater [28] than those in terol, blood pressure, other traditional risk factors, more
the general population. Taken together, these findings recently described risk factors, uremia-related factors,
strongly suggest that the traditional coronary risk factors and perhaps hemodialysis-specific risk factors on cardio-
are insufficient to account for the coronary heart diseases vascular events in this population.
in chronic hemodialysis patients. Other factors, such
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